Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma

dc.contributor.authorRaiko Kirsti
dc.contributor.authorLyytikäinen Annika
dc.contributor.authorEkman Miikka
dc.contributor.authorNokelainen Aleksi
dc.contributor.authorLahtinen Satu
dc.contributor.authorSoukka Tero
dc.contributor.organizationfi=biotekniikka|en=Biotechnology|
dc.contributor.organization-code1.2.246.10.2458963.20.98373201676
dc.contributor.organization-code2610102
dc.converis.publication-id67873883
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/67873883
dc.date.accessioned2022-10-28T12:39:30Z
dc.date.available2022-10-28T12:39:30Z
dc.description.abstract<p><br></p><p>Background and aims: Upconverting nanoparticles (UCNPs) are attractive reporters for immunoassays due to their excellent detectability. Assays sensitive enough to measure baseline level of cardiac troponin I cTnI in healthy population could be used to identify patients at risk for cardiovascular disease. Aiming for a cTnI assay of such sensitivity, the surface chemistry of the nanoparticles as well as the assay reagents and the protocol were optimized for monodispersity of the UCNP antibody conjugates (Mab UCNPs) and to minimize their non-specific interactions with the solid support.</p><p>Materials and methods: UCNPs were coated with poly(acrylic acid) via two-step ligand exchange and conjugated with monoclonal antibodies. The conjugates were applied in a microplate-based sandwich immunoassay using a combination of two capture antibodies to detect cTnI. Assay was evaluated according to guidelines of Clinical & Laboratory Standards Institute. <br></p><p>Results: The limit of detection and limit of blank of the assay were 0.13 ng/L and 0.01 ng/L cTnI, respectively. The recoveries were >90% in spiked plasma in the linear range. The within- and between-run imprecisions were <10%.</p><p>Conclusion: The results demonstrate that UCNPs enable quantification of cTnI concentrations expected in plasma of healthy individuals and could be used to identify patients at risk for cardiovascular disease.</p>
dc.format.pagerange380
dc.format.pagerange385
dc.identifier.jour-issn0009-8981
dc.identifier.olddbid178023
dc.identifier.oldhandle10024/161117
dc.identifier.urihttps://www.utupub.fi/handle/11111/35238
dc.identifier.urlhttps://doi.org/10.1016/j.cca.2021.10.023
dc.identifier.urnURN:NBN:fi-fe2021120158407
dc.language.isoen
dc.okm.affiliatedauthorRaiko, Kirsti
dc.okm.affiliatedauthorLyytikäinen, Annika
dc.okm.affiliatedauthorEkman, Miikka
dc.okm.affiliatedauthorNokelainen, Aleksi
dc.okm.affiliatedauthorLahtinen, Satu
dc.okm.affiliatedauthorSoukka, Tero
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline318 Medical biotechnologyen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline318 Lääketieteen bioteknologiafi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherELSEVIER
dc.publisher.countryNetherlandsen_GB
dc.publisher.countryAlankomaatfi_FI
dc.publisher.country-codeNL
dc.relation.doi10.1016/j.cca.2021.10.023
dc.relation.ispartofjournalClinica Chimica Acta
dc.relation.volume523
dc.source.identifierhttps://www.utupub.fi/handle/10024/161117
dc.titleSupersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma
dc.year.issued2021

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S0009898121003673-main.pdf
Size:
1.08 MB
Format:
Adobe Portable Document Format
Description:
Publisher's pdf